Kalbe Farma Tbk PTKLBF:JKT

1,840
10.00 / 0.55%
49.62m
13.93%
0.7492
Close in IDRToday's changeShares traded1 year changeBeta
Data delayed at least 15 minutes, as of May 22 2015 10:13 BST.

Consensus recommendation

As of May 09, 2015, the consensus forecast amongst 20 polled investment analysts covering Kalbe Farma Tbk PT advises investors to hold their position in the company. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Feb 14, 2015. The previous consensus forecast advised that Kalbe Farma Tbk PT would outperform the market.

Previous recommendations
Last year3 months ago2 months ago4 weeks agoLatest
Mouseover chart recommendation details.
Latest recommendation
Buy4
Outperform3
Hold9
Underperform4
Sell0
No opinion0

Share price forecast

The 19 analysts offering 12 month price targets for Kalbe Farma Tbk PT have a median target of 1,870, with a high estimate of 2,200 and a low estimate of 1,090. The median estimate represents a 1.63% increase from the last price of 1,840. View Full Financials

High+19.6 %2,200
Med+1.6 %1,870
Low-40.8 %1,090

Dividends

In 2014, Kalbe Farma Tbk PT reported a dividend of 19.00 IDR, which represents a 11.76% increase over last year. The 16 analysts covering the company expect dividends of 22.36 IDR for the upcoming fiscal year, an increase of 17.66%. View Full Financials

Div growth (TTM)+11.76 %
  • Mouseover chart for details.
  • Dividend forecast
  • Quarter 1
  • Quarter 2
  • Quarter 3
  • Quarter 4

Earnings history & estimates

On Jul 25, 2014, Kalbe Farma Tbk PT reported 2nd quarter 2014 earnings of 10.00 per share. This result under-performed the 11.97 expectation of the one analyst following the company but was the same as last year's 2nd quarter results.
The next earnings announcement is expected on Jul 23, 2015. View Full Interim Financials

Average growth rate+1.48 %

Kalbe Farma Tbk PT reported annual 2014 earnings of 44.00 per share on Mar 30, 2015. View Full Annual Financials

Average growth rate+12.64 %
  • Mouseover chart for details.
  • Reported results
  • Forecasts
  • Pos/Neg restatement

Revenue

PT Kalbe Farma Tbk had 1st quarter 2015 revenues of 4.2467bn. This missed the 4.4966bn estimate of the one analyst following the company. This was 7.88 % below the prior year's 1st quarter results. View Full Interim Financials

Average growth rate+1.25 %

PT Kalbe Farma Tbk had revenues for the full year 2014 of 17.3685bn. This was 8.54% above the prior year's results. View Full Annual Financials

Average growth rate+14.39 %
  • Mouseover chart for details.
  • Reported results
  • Forecasts
  • Pos/Neg restatement
© Thomson Reuters Click for restrictions.

All markets data located on FT.com is subject to the FT Terms & Conditions.

All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.